AUTHORS
Antonio Curti Sr, MD, Sabina Chiaretti, MD2, Mario Delia3, Francesco Grimaldi, MD4, Federico Lussana, MD, PhD5, Lisa Argnani6, Robin Foà, MD7, Nicola Stefano Fracchiolla, MD8
AFFILIATIONS
1 Istituto di Ematologia 'Seràgnoli', IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
2 Division of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
3 U.O.C. Ematologia con Trapianto, Azienda Ospedaliero-Universitaria-Consorziale Policlinico, Bari, Italy
4 Hematology Section, PO San Giuliano, ASL Napoli 1 Nord, Napoli, Italy
5 Hematology and Bone Marrow Transplant Unit, Azienda Socio Sanitaria Territoriale Ospedale Papa Giovanni XXIII, Bergamo, Italy, Department of Oncology and Hematology, Università degli Studi di Milano, Milan, Italy., Bergamo, Italy
6 Department of Medical and Surgical sciences (DIMEC), University of Bologna, Bologna, Italy
7 Ematologia, Dipartimento di Medicina Traslazionale e di Precisione, “Sapienza” Università di Roma, Roma, Italy
8 Hematology, IRCCS Ca’Granda Ospedale Maggiore Policlinico di Milano, MILAN, Italy
ABSTRACT
Background. Relapsed or refractory (R/R) Philadelphia- B-cell acute lymphoblastic leukemia (Ph- B- ALL) has been associated with a poor outcome. Conventional salvage chemotherapy yields complete remission (CR) rates <40% and a median overall survival (OS) of less than 6 months. The therapeutic paradigm has changed with targeted immunotherapies: blinatumomab (blina), inotuzumab ozogamicin (InO), and CD19-directed CAR-T cells. These agents significantly improve CR and measurable residual disease (MRD) negativity, facilitating access to allogeneic hematopoietic stem cell transplant (allo-HSCT). The optimal sequencing of these therapies remains however undefined, and clinicians must balance disease burden, patients (pts) fitness, and treatment history.
Methods. To establish clinical recommendations on immunotherapy sequencing, a panel of expert hematologists integrated clinical trial evidence with real-world data from the Campus ALL National network. The survey collected retrospective data from 36 Italian centers (both CAR-T cell accredited and non-accredited) managing adult R/R Ph- B-ALL patients between January 2021 and December 2025. The analysis focused on treatment sequences, age-related treatment selection, previous transplant exposure, and organizational barriers affecting access to treatment.
Results. Treatment sequences were reported for 295 pts, including 78 CAR-T cells. The most frequent strategies were InO alone (57), blina alone (49), blina followed by HSCT (39), InO followed by HSCT (29), chemotherapy alone (23), CAR-T cells alone (13). More complex sequences including CAR-T cells were: CAR-T cells followed by HSCT (7), InO followed by CAR-T cells (23), InO followed by CAR-T cells and HSCT (11), InO followed by blina and CAR-T cells (1 with HSCT intensification; 1 without HSCT intensification), blina followed by CAR-T cells (5 with HSCT intensification; 7 without HSCT intensification), blina followed by InO and CAR-T cells (3 with HSCT intensification; 7 without HSCT intensification).
Age significantly influenced treatment selection: among pts receiving InO alone, 42.1% were aged >65 years, whereas CAR-T cell-based strategies were predominantly used in younger pts. In particular, 76.9% of CAR-T cells alone pts and 100% of CAR-T cells followed by HSCT pts, were aged ≤55 years.
CAR-T cell therapy was also frequently used as a salvage strategy after failing a prior HSCT, including, among the most frequent sequences, 7/20 pts treated with CAR-T cells (2 with HSCT intensification; 5 without HSCT intensification), 10/34 pts treated with InO followed by CAR-T cells (9 without HSCT intensification; 1 with HSCT intensification), and 7/12 pts treated with blina followed by CAR-T (3 with HSCT intensification; 4 without HSCT intensification). InO emerged as a cytoreductive bridge, particularly for high-burden disease, a setting in which blina is typically less effective and requires preventive debulking. With regard to accessibility to immunotherapy, the following items that require improvement emerged from the survey:
Referral of pts with advanced disease or clinical deterioration with consequent treatment ineligibility (reported in 14 cases across blina, InO, and CAR-T cells).
Lack of caregiver support.
Insufficient inpatient availability.
Liver disease (for InO treatment).
The 3-4 week "vein-to-vein" manufacturing interval for CAR-T cells and the possibility of disease progression.
Conclusions. Real-world data from the Campus ALL survey highlight the increasing integration of immunotherapies in the management of R/R Ph- B-ALL. Treatment selection and sequencing were strongly influenced by age, disease burden, prior transplantation, and access-related factors. For fit, transplant-eligible pts, the sequence InO followed by CAR-T cells and allo-HSCT represents an appealing clinical strategy that may contribute to achieve a rapid debulking, deep molecular remission, and long-term OS. InO provides an optimal bridge by reducing tumor burden in preparation for CAR-T cell therapy without exerting selective pressure on CD19 expression. Strategies of MRD driven post-CAR -T intensification with HSCT warrant future specifically tailored studies. To maintain and maximize the potential of these curative sequences, there is a continuous need to optimize hub-and-spoke referral networks, ensuring timely specialist evaluation to prevent disease progression or clinical complications that may preclude access to advanced immunotherapies.
DISCLOSURES
Antonio Curti Sr, MD: AbbVie, Servier, Otsuka, Pfizer, Jazz Pharmaceuticals, Novartis, Daiichi-Sankyo - Honoraria; AbbVie, Servier, Otsuka, Pfizer, Jazz Pharmaceuticals, Novartis, Daiichi-Sankyo - Consultancy (Includes expert testimony)